Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of molecular medicine"
DOI: 10.3892/ijmm.2018.3759
Abstract: Benign prostatic hyperplasia (BPH) is one of the leading causes of male reproductive disorders. Therapeutic agents currently in use have severe side effects; therefore, alternative drugs that exhibit improved therapeutic activity without side effects are… read more here.
Keywords: prostatic hyperplasia; benign prostatic; gv1001; testosterone induced ... See more keywords